The short answer
BPC-157 is not FDA-approved for any indication and is not on the FDA's 503A or 503B bulks lists, so compounding pharmacies have no lawful pathway to compound it from bulk. Its April 2026 removal from Category 2 was procedural — the nominations were withdrawn — and the July 2026 advisory committee vote favoring it is non-binding until FDA completes rulemaking.
What is the actual regulatory status right now?
Three facts define it, and they are frequently conflated.
BPC-157 has never been FDA-approved. There is no approved BPC-157 product, no approved indication, and no recognized USP or NF monograph.
It was removed from Category 2 in April 2026 for procedural reasons. FDA's interim list of bulk drug substances nominated for use under section 503A sorted substances into categories; Category 2 held substances raising significant safety risks. On 15 April 2026, FDA removed BPC-157 along with eleven other peptides — including TB-500, Semax, Epitalon, KPV, MOTS-c, DSIP, LL-37, injectable GHK-Cu and Melanotan II — because the parties who nominated them withdrew their nominations. Withdrawal of a nomination removes the substance from the list being evaluated. It is not a safety clearance, and FDA did not move any of them to Category 1.
The July 2026 advisory vote is a recommendation, not a rule. At its meeting on 23–24 July 2026, FDA's Pharmacy Compounding Advisory Committee voted narrowly — 8 to 6 with one abstention — to recommend that BPC-157 be added to the 503A bulks list, over the contrary recommendation of FDA's own reviewers, who cited short and underpowered studies. The committee similarly favored KPV, TB-500, MOTS-c, Semax and epitalon, and voted against emideltide. PCAC is advisory only. FDA must still weigh the recommendation, publish a proposed rule, take public comment and issue a final rule. No final rule has been issued.
So can a pharmacy legally compound it?
| Requirement under section 503A | BPC-157 |
|---|---|
| Complies with a USP/NF monograph | No |
| Is a component of an FDA-approved drug | No |
| Appears on the 503A bulks list | No |
| On the 503B bulks list (outsourcing facilities) | No |
Section 503A permits a compounding pharmacy to use a bulk drug substance only if it satisfies one of the first three rows. BPC-157 satisfies none of them. The same analysis applies at 503B. As of today, a compounding pharmacy that produces BPC-157 from bulk is compounding with a substance it has no statutory basis to use, and the resulting product is an unapproved new drug.
A physician may write whatever prescription clinical judgment supports, but a prescription that cannot be lawfully filled by any compliant pharmacy is not a workable clinical plan. Material sold online as "research use only" is not manufactured for human administration, is not subject to compounding quality standards, and its purchase and administration to patients does not become lawful because a clinician signs for it.
What else should a practice weigh?
Sourcing and identity. Independent testing of consumer peptide products has repeatedly found content that differs from the label. Without a compliant supply chain there is no way to establish what was administered — which is fatal both clinically and evidentially if something goes wrong.
Athletes. BPC-157 falls under the World Anti-Doping Agency's S0 category of non-approved substances, prohibited at all times. Any patient in tested sport should be told this explicitly.
Advertising. Claims that BPC-157 heals tendons, repairs gut lining or accelerates recovery are health claims requiring competent and reliable scientific evidence under the FTC's health products guidance, and marketing an unapproved drug for disease treatment also raises FDA drug-labeling exposure.
What this means for your paperwork
If your practice is watching this space, keep a dated regulatory status memo in the policy manual — one page, citing the April 2026 Category 2 removal, the July 2026 PCAC vote, and the fact that no final rule exists — with a scheduled re-check. This is the single fastest-moving area in aesthetic medicine right now, and any consent form or website copy written before July 2026 is already describing a different regulatory world.
If you do treat, the file should show the good faith exam and indication, an explicit written acknowledgment that the substance is not FDA-approved and not on the bulks lists, disclosure that safety and efficacy are not established for the proposed use, the named source and its licensure status, lot and certificate of analysis, and the anti-doping disclosure. Do not use consent language that describes the product as approved, cleared, or permitted for compounding, and do not let marketing copy outrun what the record can support.
Related questions
This answer is educational and is not legal or medical advice. Requirements vary by state and change over time — verify with your own legal and clinical advisors before applying anything here in practice.